On December 4, 2019 Moffitt Cancer Center, a leader in the clinical care and research of blood malignancies, reported that it will present its top clinical research at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, Dec. 7-10 at the Orange County Convention Center in Orlando, Fla (Press release, Moffitt Cancer Ctr, DEC 4, 2019, View Source [SID1234551919]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Moffitt faculty are authors on more than 80 abstracts accepted for this year’s meeting, and will be presenting 37 including the four following oral presentations:
Date/Time: Saturday, Dec. 7, 3:00 p.m.
Abstract: 245
Title: Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Presenter: Michael Jain, M.D., Ph.D., Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy
Location: Hall E2, Level 2
Date/Time: Monday, Dec. 9, 8:00 a.m.
Abstract: 569
Title: The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Presenter: David Sallman, M.D., Assistant Member, Department of Malignant Hematology
Location: W311EFGH, Level 3
Date/Time: Monday, Dec. 9, 11:15 a.m.
Abstract: 676
Title: Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Presenter: David Sallman, M.D., Assistant Member, Department of Malignant Hematology
Location: W311ABCD, Level 3 (Orange County Convention Center)
Date/Time: Monday, Dec. 9, 4:45 p.m.
Abstract: 842
Title: Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study – an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health
Presenter: Alan F. List, M.D., Senior Member, Department of Malignant Hematology
Location: W311ABCD, Level 3
If you’d like to schedule an interview with any Moffitt experts during the annual meeting, please contact Kim Polacek at [email protected].
You can also learn more about the cancer center by visiting booth no. 1464 on the exhibit floor during the meeting.